Of these, one of the most represented PIK3CA mutations (affecting 4% of melanoma patients, according to COSMIC data) with a pathogenetic role in drug resistance is the PIK3CA H1047R mutation associated with both anti-BRAF and anti-MEK inhibitors of drug resistance [27,28,29]. The gene discussed is BRAF; the disease is melanoma.